Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > Topline data

<< Previous

Bullboard Posts

Next >>

Post by talisman47on Mar 31, 2021 2:26pm

257 Views

Post# 32915626

Topline data

Overall the data seems to come across pretty good. I would like to hear from a pharma or scientist expertise that would give their opinion of the data and how they would rate it.

Was really hoping the stock was going to go up today.....very dissapointing ! On a positive thought it only has gone down 5 cents.

Still believe more good is possible.....

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing